---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-040412"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:24:52.062306+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protara Q2 net loss $12.8M; cash $145M; on track for TARA-002 IND by year-end

## Summary
- Cash $145M; net loss $12.8M ($1.14/sh) vs $7.1M ($1.22/sh) in Q2 2020.
- R&D expense rose to $5.9M (from $2.5M) on TARA-002; G&A $6.9M (from $4.8M).
- Completed IND-enabling studies for TARA-002 in NMIBC; on track to file IND H2 2021 & start Phase 1.
- GMP comparability for TARA-002 on track for year-end; seeking FDA alignment on LM trial design.
- Appointed Dr. Jane Huang (BeiGene CMO) to Board of Directors in June 2021.

## SEC filing metadata
- accession: 0001213900-21-040412
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/0001213900-21-040412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/ea145229-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-040412
- JSON: https://secwatch.observer/filing/0001213900-21-040412.json
- Plain text: https://secwatch.observer/filing/0001213900-21-040412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.